Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Isis Innovation and Parkwalk Advisors announced today that the University of Oxford Isis Fund II has raised over £2 million, exceeding its funding target, and will close to new investors.

The fund achieved its initial target in less than four weeks and will close at almost twice that level.

Isis Innovation executive director Linda Naylor said: “In 2014, Isis Innovation oversaw a record £2.6m in proof-of-concept funding flow into over twenty new Oxford technologies and ventures. The first University of Oxford Isis Fund was a cornerstone of this achievement, and we already have a pipeline of promising technologies which will apply to this second Fund over the coming year.

“These Funds will again play a critical role in providing finance so new companies are properly resourced for the initial stages of commercial product development.”

The University of Oxford Isis Fund I invested in stroke-diagnostics specialist Brainomix which went on to raise £1.2m and won numerous awards and grants, Oxtex, the developer of a novel intelligent tissue expander, Salunda, the manufacturer of a contactless sensor for condition monitoring and automated sentiment analysis company TheySay.

Parkwalk Advisors’ Moray Wright said: “These Funds provides private investors, particularly University of Oxford alumni and friends, with quite a unique chance to invest in early stage technology companies as they spin-out of the University.

“And as these companies become successful, investors in the funds also stand to gain from the tax reliefs offered under the Enterprise Investment Scheme and Seed Enterprise Investment Scheme.”

Since 1987, Isis Innovation has been responsible for creating spin-out companies based on academic research from the University of Oxford. It has spun-out a new company every two months on average. Over £266 million in external investment has been raised by Isis spin-out companies since 2000, and five are currently listed on London’s AIM market.

Parkwalk Advisors is a UK technology-specialist EIS fund management firm. Parkwalk aims to launch the University of Oxford Isis Fund III in Q4 2015 or Q1 2016. For further details please contact the Parkwalk funds team on 020 7759 2285.

About Isis Innovation

Isis Innovation is the research and technology commercialisation company of the University of Oxford. We provide access to technology from Oxford researchers through intellectual property licensing, spin-out company formation and material sales, and to academic expertise through Oxford University Consulting.

Isis is the highest university patent filer in the UK and is ranked 1st in the UK for university spin-outs, having created more than 100 new companies in 25 years. In the last financial year we completed 503 licenses and consulting agreements. Isis Enterprise, our innovation management consultancy, signed 85 deals with university, government and industrial clients from offices around the world.

Isis was named ‘Technology Transfer Unit of the Year 2014’ by Global University Venturing.

For updates on innovations from Oxford, follow Isis on LinkedIn and Twitter or subscribe at www.isis-innovation.com 

About Parkwalk Advisors

Specialising in University spin-out companies, Parkwalk invests in innovative UK high-growth companies across various stages of their development: from growth, development and commercial capital through to acquisition finance. Investments range from early stage to AIM-listed. Parkwalk’s EIS Funds seek significant capital gains with the substantial benefits offered under the Enterprise Investment Scheme. 

For updates from Parkwalk, please go to www.parkwalkadvisors.com or follow us on Twitter

For further details please contact the Parkwalk funds team on 020 7759 2285.

Media enquiries to:

Renate Krelle
Media & Business Communications Manager, Isis Innovation Ltd
renate.krelle@isis.ox.ac.uk
T: 01865 280867

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Oxford to receive £7 million to turn bright ideas into global opportunities

The University of Oxford has been awarded more than £7 million, the highest amount of funding given to organisations across the UK, in the latest round of UK Research and Innovation’s (UKRI) Impact Acceleration Account (IAA) funding - aimed at fueling the best, brightest and most disruptive ideas from Uk research institutions.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.